跳到正文
cccskills
免费在 GitHub 公开

es-hcm-ugps8-surgical-consult-para-carcinoma

Advises surgical referral for parathyroid carcinoma when feasible after achieving control of severe hypercalcemia. Triggered when a clinician confirms parathyroid carcinoma and inquires about curative options following medical stabilization of hypercalcemia.

中文简介正在准备中。当前显示原文说明。

实测评分 未实测

查看安装方法

包含的文件(1)

  • SKILL.md2.6 KB

SKILL.md(原文)

安装前可以查看交给 AI 代理的指令内容。

Pursue surgical consultation for definitive treatment of parathyroid carcinoma

STEP 1 — Gather Information

Confirm parathyroid carcinoma diagnosis (pathology, imaging showing invasive features, markedly elevated PTH). Assess serum calcium level (corrected SCa >14 mg/dL indicates severe HCM), renal function, volume status, and current medical therapy (calcimimetic, antiresorptive). Ensure patient is medically stabilized with IV fluids and antiresorptive agents, with calcium trending downward.

STEP 2 — Rule In / Rule Out

Is parathyroid carcinoma confirmed or highly suspected?

  • Yes → proceed to Step 3.
  • No → consider other causes of HCM (malignancy, hyperparathyroidism) and manage per etiology-specific algorithm.

STEP 3 — Classify or Stratify

Is severe hypercalcemia (SCa >14 mg/dL) controlled?

  • Calcium normalized or trending toward normal with medical therapy → proceed to Step 4.
  • Persistent severe HCM despite medical therapy → intensify medical management (e.g., add calcimimetic or antiresorptive) and re‑evaluate before surgery.

STEP 4 — Decide

If parathyroid carcinoma confirmed and severe HCM controlled, pursue surgical consultation for definitive resection.
If HCM remains uncontrolled, continue medical therapy (calcimimetic ± antiresorptive) and reassess calcium control daily.

Clinical Guardrails / Mimics / Pitfalls

Do not proceed to surgery without achieving calcium control due to risk of perioperative arrhythmias and neurologic instability. Avoid delaying definitive surgery in resectable disease once calcium is stabilized. Recognize that surgery may not be curative if metastatic disease is present. Pitfalls include mistaking parathyroid adenoma for carcinoma, overlooking invasive features on imaging, and operating in uncontrolled HCM leading to hemodynamic collapse.

Concrete Clinical Example

A 58‑year‑old with known parathyroid carcinoma presents with fatigue, nausea, and SCa 15.2 mg/dL. After IV zoledronic acid and cinacalcet, SCa decreases to 10.8 mg/dL over 48 hours. Surgical consultation is pursued; intraoperative findings show invasive capsular breach, and postoperative PTH normalizes.

Source: Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac621

评价

还没有评价。欢迎分享你的使用感受。

评论

无需登录即可发表。欢迎分享使用感受、提问,或说明在哪些环境下无法运行。

还没有评论。来写第一条吧。

提交后会立即公开。请勿填写邮箱、电话等个人信息。URL 最多 2 个。

0 / 1000 字

此表单受 reCAPTCHA 保护,适用 Google 的隐私权政策和服务条款。

同一仓库的技能

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

查看 dromlakhani 的全部技能

报告此技能的问题